Tafasitamab (Monjuvi)

From HemOnc.org - A Hematology Oncology Wiki
Revision as of 16:06, 11 December 2014 by Jwarner (talk | contribs) (Created page with "==Mechanism of action== Anti-CD19 antibody with an engineered Fc region to enhance Fcγ receptor binding affinity ==Preliminary data== ===[[Chronic lymphocytic leukemia (CLL)...")
(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)
Jump to navigation Jump to search

Mechanism of action

Anti-CD19 antibody with an engineered Fc region to enhance Fcγ receptor binding affinity

Preliminary data

Chronic lymphocytic leukemia (CLL) and Small lymphocytic lymphoma (SLL)

  1. Woyach JA, Awan F, Flinn IW, Berdeja JG, Wiley E, Mansoor S, Huang Y, Lozanski G, Foster PA, Byrd JC. A phase 1 trial of the Fc-engineered CD19 antibody XmAb5574 (MOR00208) demonstrates safety and preliminary efficacy in relapsed CLL. Blood. 2014 Dec 4;124(24):3553-60. Epub 2014 Oct 9. PubMed
Retrieved from "https://hemonc.org/w/index.php?title=Tafasitamab_(Monjuvi)&oldid=6299"